Pricing
  1. US-listed companies
  2. KYNTRA BIO, INC.
  3. Financials
  4. Capital expenditures

KYNTRA BIO, INC.【KYNB】

Market cap
$28.19M
P/E ratio
SummaryFinancials
Period EndCapital expenditures (Million USD)YoY (%)
Dec 31, 2024-0-89.44%
Dec 31, 2023-3-32.67%
Dec 31, 2022-4-27.86%
Dec 31, 2021-5+29.84%
Dec 31, 2020-4-30.68%
Dec 31, 2019-6-28.15%
Dec 31, 2018-8-5.65%
Dec 31, 2017-8+578.91%
Dec 31, 2016-1-36.67%
Dec 31, 2015-2

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)